Drugs / HRS-9815
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06062355 | Oct → Dec 2023 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06062355 ↗ |
| Modality | Diagnostic / imaging agent | “for PET/CT imaging” NCT06062355 ↗ |